Leading bioinformatics software company Qlucore has agreed a two-year license with the large pharmaceutical company Boehringer Ingelheim worth approximately 1.67 million SEK. As a leading pharmaceutical company engaged in research and development across multiple locations worldwide and a previous customer of Qlucore, the license enables global utilization of Qlucore Omics Explorer software.
 
Qlucore Omics Explorer is software designed for research in pharmaceuticals and biotechnology, catering to both commercial and academic users. Through interactive visualization coupled with rapid calculations, users can identify crucial information within often vast and complex datasets. The software is currently utilized by researchers in over 200 organizations across more than 20 countries, to publish over 1000 scientific articles.
 
“We are extremely proud that Boehringer Ingelheim has once again chosen to order Qlucore Omics Explorer licenses for use in their research and development,” says Carl-Johan Ivarsson, CEO of Qlucore.

About Qlucore

Qlucore is a leading provider of new generation intuitive bioinformatics software for research and precision and companion diagnostics. Qlucore’s mission is to make it easier to analyze the huge amounts of complex data generated by innovations in the fields of genomics and proteomics by providing powerful visualization-based bioinformatics data analysis tools for research and precision diagnostics. Qlucore Omics Explorer software is a easy to use bioinformatics software for research in the life science, plant- and biotech industries, as well as in academia. Qlucore Diagnostics and Qlucore Insights are software platforms with built in AI-based machine learning for multi-omics companion and precision diagnostics. Qlucore was founded in 2007 in Lund, Sweden and has customers in about 25 countries around the world, with sales offices in Europe and North America, and distribution in several countries in Asia. Qlucore is listed on the Nasdaq First North Growth market. www.qlucore.com